TScan Therapeutics, Inc. (TCRX)
0.2377
+0.03
(+12.87%)
USD |
NASDAQ |
Oct 15, 16:00
0.2377
0.00 (0.00%)
After-Hours: 20:00
TScan Therapeutics Debt to Equity Ratio : 1.317 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.317 |
| March 31, 2026 | 0.9548 |
| December 31, 2025 | 0.7646 |
| September 30, 2025 | 0.6639 |
| June 30, 2025 | 0.5472 |
| March 31, 2025 | 0.4616 |
| December 31, 2024 | 0.4041 |
| September 30, 2024 | 0.3944 |
| June 30, 2024 | 0.3568 |
| March 31, 2024 | 0.7462 |
| December 31, 2023 | 0.6127 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.5148 |
| June 30, 2023 | 0.4603 |
| March 31, 2023 | 1.094 |
| December 31, 2022 | 0.8647 |
| September 30, 2022 | 0.2906 |
| June 30, 2022 | 0.0398 |
| March 31, 2022 | 0.0388 |
| December 31, 2021 | 0.0376 |
| September 30, 2021 | 0.0368 |
| June 30, 2021 | 0.0683 |
| March 31, 2021 | 0.0653 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
| Imunon, Inc. | 1.873 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 171.45M |
| Total Liabilities (Quarterly) | 102.43M |
| Shareholders Equity (Quarterly) | 69.02M |
| Current Ratio | 3.372 |
| Net Debt Paydown Yield | 1.85% |